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An ApoE-A(S inhibition cpmplex in AP fibril extension 
Stephen J Wood, Winnie Chan and Ronald Wetzei 
Background: Literature reports differ dramatically in showing that 
apolipoprotein E either facilitates or inhibits AQ aggregate formation in vitro. 
Resolution of the nature of the ApoE-AP interaction is critical for progress 
towards understanding its possible role in the modulation of Alzheimer’s disease. 
Results: Here, we show that purified ApoE-A@ co-aggregate is a poor seed of 
fibril formation. We also demonstrate ApoE inhibition of Ap fibril growth in four 
independent aggregation assays, arguing that the poor fibril formation observed 
under these conditions is real and not an analytical artifact. We also directly 
show ApoE binding to immobilized AP fibrils by surface plasmon resonance. 
Conclusions: The results suggest a unifying model in which ApoE binds to AP 
fibril seeds and nascent nuclei to generate stable complexes that inhibit the rapid 
extension of mono-component AP fibrils but at the same time can foster continued 
slow growth of mixed ApoE-A@ aggregates. In viva co-aggregate formation may 
be important in many examples of pathological protein misassembly. 
Introduction 
One of the genetic loci associated with Alzheimer’s disease 
(AD). is the apolipoprocein E (ApoE) gene. Individuals 
carrying copies of the relatively rare E4 allele (ApoE4) are 
more at risk for developing AD than carriers of the E2 
(ApoE2) and E3 (ApoE3) alleles [I]. Molecular expla- 
nations for the genetics have been prompted by the 
immunochemical deccction of ApoE as a component of the 
AP plaques that are a hallmark of Alzheimer’s pathology 
[Z-4]. The role of AP in the etiology of Alzheimer’s 
disease (AD} is unproven [5,6], however, and it remains 
possible that ApoE affects the development of AD 
independently of an A@-related mechanism. At the same 
time, the recent identification of ApoE as a risk factor in 
A@ amyloid diseases unrelated to - or independent of - 
Alzheimer’s disease [7-91, as well as a correlation of 
enhanced plaque load and AD progression with the E4 
isoform of ApoE [lo], add further support to arguments 
that ApoE modulation of amyloid formation is important in 
determining the severity of AD. 
The possibility of a relevant molecular association between 
ApoE and AP has inspired a number of investigations on 
the in V.&-O interactions of these two polypeptides 
[4,11-Z]. No consistent model for the role of ApoE in 
fibrillogenesis has emerged, however, with some groups 
reporting stimulation, and others inhibition, of aggregate 
formation in the presence of ApoE isoforms. 
Previously we produced the three major human isoforms 
of ApoE in Esc/&&u coli and studied their interactions 
with chemically synthesized A@ under native solution 
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conditions bn vitp.0 [Zl,ZZ]. We conducted two kinds of 
experiments that gave seemingly contradictory results - 
results chat mirror, in some ways, the conflicting literature 
reports on the ApoE-AS interaction. Working at relatively 
high ApoE concentrations, we found chat all three ApoE 
isoforms form soluble high molecular weight co-aggregates 
with AP that can be isolated by gel filtration chromato- 
graphy [Zi]. At much lower ApoE concentrations, we 
found that all three ApoE isoforms strongly inhibit the 
initiation of A@ fibril formation conducted either with the 
addition of pre-formed A@ aggregates (‘seeding’) or in the 
absence of exogenous seeds (‘nucleation’) [Z?]. 
Here we report results linking these two previous studies, 
in which we,demonscrare that the high moIecular weight 
complex of ApoE and AP isolated by gel filtration has 
little or no seeding ability for A@ fibril formation. These 
new data have led us co propose a model which may help 
explain so&e apparently conflicting results reported 
previously. The model implies chat it should be possible 
to develop therapeutics which, at relatively low con- 
centrations, might be able to slow the growth of pre- 
existing fibrils, as well as block the nucleation of new 
ones. Selective aggregation and deposition of normally 
well-behaved proteins via their misfolding and mis- 
assembly is now recognized as an important component of 
a number of human diseases and other biological 
functions 1231. The ability of a growing protein aggregate 
to incorporate other protein molecules into the matrix 
may account for examples of cross-nucleation, inhibition, 
and aggregate toxicity in some cases of pathologicat 
protein deposition [24]. 
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Results Figure 1 
ApoE &forms are effective inhibitors of the seeding of 
fibril formation by preformed AP fibriis [Z, ZS]. This 
is true for both l-40 and l-42 versions of AP, and for 
plasma-derived and E. &-derived human ApoE [ZZ]. 
Figure 1 shows that AP - if it has been previously treated 
with 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) to remove 
preexisting aggregates [22,26] - must be incubated for 
four days before significant fibril formation begins. If the 
reaction is supplemented with a small amount (0.02 % by 
weight of the amount of Ap in the fibril formation 
reaction) of AD fibril, however, fibril formation begins 
after one day. Addition of nM concentrations of ApoE 
delays the onset of AP fibril formation in such seeded 
reactions, with 150 nM providing a delay of over seven 
days - well beyond the lag time normally seen in an 
unseeded reaction (Fig. la). This effect cannot be due to 
the sequestration of A@ by ApoE, since the binding 
capacity of ApoE for non-aggregaccd AP is only about four 
molecules AP per ApoE tetramer [Zl]; this would, at most, 
neutralize 1 % of the AP in these fibril formation reac- 
tions. The effect is also not due to the ability of ApoE to 
compromise the dye binding assays. When ApoE was 
added to a Conga red assay of pre-formed fibrils, at three 
times the concentration at which it is typically present 
in these assays, no difference in signal was observed (C, = 
6.8 + 0.2 in the absence of ApoE, C, = 6.7 f 0.1 in the 
presence of ApoE). 
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Since different aggregated states of A@ have different 
responses in the Congo red binding assay [ZG], we were 
concerned that the apparent lack of fibril growth during the 
extended lag phase of ApoE-inhibited reactions might be 
an artifact of the technique for following fibrii formation. 
To address this, we conducted a fibril-growth experiment 
in the presence and absence of ApoE, monitoring the 
reactions using Congo red binding, thioflavin T binding, 
and HPLC analysis for residual soluble pepcide. The 
results of the three analyses are in excellent agreement 
(Fig. Z), showing that, in the presence of ApnE, there is no 
significant growth of AP fibrils over the course of the 
experiment. In principle, it might be possible that 
significant ApoE-AD co-aggregates form over the course of 
the experiment which are refractory to the detection 
methods used. The thioflavin T response to isolated 
ApoE-Ap co-aggregate is identical to its response to mono- 
component Ap fibrils, however (see below). This would 
appear to rule out the formation of significant levels of both 
soluble and insoluble high molecular weight ApoE-AP co- 
aggregates in the ApoE-containing reaction (Fig. 2). 
Amyloid fibril formation of 58 CM HFIP-treated A# in PBS at 37’ C as 
monitored by Congo red binding. (a) ApoE inhibition of nucleation of 
fibril formation by exogenous fibril seed. An unseeded reaction (black n ) 
requires four days before fibril formation begins. Other time courses 
shown are from reactions seeded with 0.02 %, by weight, of the amount 
of HFIP-treated AD in the reaction, and in addition containing 0 nM 
(magenta 0), 0.3 nM (green n), 30 nM (purple A), or 150 nM (cyan l ) 
tetrameric ApoE3. (b) Inability of isolated AP-ApoE complex to efficiently 
nucleate fibril formation by AP. With no additions (btack H), onset of fibrl 
formation was delayed for four days. Addition of 0.02 % by weight of AP 
fibrils (red A) gives onset of fibril formation after a one-day lag, while 
addition of 10 % by weight of fibrillar AP (green 0) gives immediate fibril 
formation. Freshly prepared ApoE3-A!3 complex was assessed far its AP 
content and added to an unseeded fibrit formation reaction to deliver 
0.02 % by weight (purple A) or 10 % by weight of A$ (magenta 0). Prior 
formation is critical for the poor seeding ability of complex: independent 
addition of 10 9’0 by weight of A!3 fibrils, along with 23 nM ApoE 
tetramer (a proportion identical to that found in isolated complex) exhibits 
normal, efficient seeding of fibril formation (cyan 0). 
As previously described [26], AQ fibrils grown under 
unstirred conditions do not exhibit appreciabie turbidity. 
For this reason, turbidity measurements were not useful 
in monitoring the reactions shown in Figure 2. Buti 
for reasons that are unclear, fibril formation reactions do 
generate turbid suspensions when conducted under stirred 
conditions [18]. To further confirm our findings with the 
aid of the turbidity assay, and to confirm the observations’ 
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Course of fibril formation in unagitated reactions, by multiple methods 
of detection. Fibril formation reactions were set up as described in the 
legend to Fig. 1 with 58 FM HFIP-disaggregated AP and 0.02 o/b by 
weight AP fibril as seed. Reactions were conducted in the absence 
(closed symbols) or presence (open symbols) of 150 nM ApoE3, and 
were monitored for fibril formation by Congo red binding (O,# and 
thioflavin T binding (A,*), and for soluble Ap by HPLC @,N). 
of Lansbury and coworkers [ 181, we conducted fibril for- 
mation reactions in the presence and absence of ApoE in a 
shaken microtiter plate. Ap aggregation was monitored by 
turbidity and Congo red binding. In a shaken reaction 
containing 420 PM HFIP-treated Ap, rapid aggregation 
takes place after a time lag of 1.5 h (Fig. 3). Although 
delays in the generation of detectable turbidity in aggre- 
gation reactions can sometimes be attributed to the non- 
linearity of light scattering with respect to particle size 
1271, the time lag observed in the turbidity profile in 
Figure 3a is probably associated with a nucleation event, 
since a similar lag is observed when the same reaction is 
monitored by Congo red binding (Fig. 3b). Aggregation of 
AP, as measured by both turbidity and Congo red binding, 
is suppressed for at least five hours under these conditions 
when the reaction is conducted in the presence of 4 pbl 
ApoE (Fig. 3). 
We have previously demonstrated that ApoE is able to co- 
aggregate with AP in the solution phase 12.11. The ability 
of ApoE to inhibit AP fibril extension suggests that ApoE 
must also bind to extension-competent AP fibrils in the 
solid phase. We used surface plasmon resonance (SPR) to 
explore this possibility. Figure 4a shows that aggregated 
A@ non-covalently adds to a biosensor chip onto which A@ 
has been chemically attached. As the aggregated A@ in 
this preparation has the ability to seed fibril formation [ZZ] 
and as it reveals fibrils that can be detected by electron 
microscopy [ZS], we interpret these results to indicate that 
the aggregated material bound to the covalent-AP sensor 
chip is fibrillar. The fact that HFIP-disaggregated AP 
r- 
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Course of fibril formation in shaken reactions, by two methods of 
detection. Reactions were conducted with shaking in a microtitre plate 
in the presence (0) or absence (A) of ApoE, as described in Materials 
and methods. (a) Reactions monitored by turbidity {apparent 
absorbance at 405 nm). (b) Reactions monitored by Congo red. 
does not detectably bind to the covalent-AD chip (trace 2 
of Fig. 4a) also suggests that the strong binding found for 
untreated AP solutions is due to the binding of pre- 
existing A@ aggregates to the chip. Low molecular weight 
forms present in HFIP-treated A@ may also bind to the 
Ap attached to the sensor chip, but may give a very low 
signal due to their low mass. 
Figure 4b shows that ApoE binds strongly to the sensor 
chip containing this aggregated Ap. The sensogram 
shows a rapid binding of ApoE to a plateau value that 
persists until the end of the l&and addition phase, In the 
buffer wash’ phase, a portion of the bound ApoE disso- 
ciates, but the majority of the ApoE remains more tightly 
bound, suggesting CWQ classes of binding sites for ApoE 
on the fibrils. The slowly dissociating ApoE site may 
reflect additiona integration of the ApoE into the AP 
fibril matrix, generating a complex that may resemble 
the previously reported solution phase ApoE-A@ [Zi]. 
Ther.G. are a limited number of tota ApoE sires on the 
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Figure 4 
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Binding of ApoE to aggregated A8 
evaluated by surface plasman resonance 
(SPR) 1411. Sample flowed over the sensor 
chip for 300 s (from 150 s to 450 s on the 
time axis shown) at a rate of 5 Al min-‘. The 
drop in reference units (RU) at 150 s and 
reciwety of RU at 450 s are due to a 
refractive index difference between 
equilibration/running buffer and sampie 
buffer. The sensor chip was modified by 
covalent attachment of A@ (Materials and 
methods). (a) Non-covalent binding of 
aggregated AS to a sensor chip previously 
modified by covalent attachment of A8. Curve 
1 shows that injection of 100 J.LI min-’ Af3, in 
Hepes-buffered saline (HBS), pH 7.4 
containing 0.1 % Tween-PO, over a native, 
unmodified chip gives no binding. Curve 3 
shows that, in contrast, an identical sample of 
A@ exhibits strong, irreversible binding to a 
sensor chip which was previously modified 
with 500 RU of covalently attached A8. If the 
A8 is tigorousiy disaggregated by HFIP 
pretreatment, however, it displays no 
detectable binding to the sensor chip 
containing covalently attached A8 (curve 2). 
(b) Binding of 25 p.1 min-’ ApoE in HBS- 
Tween to a sensor chip containing 
immobilized aggregated A8 (see (a)). The 
sharp drop in RU at about 900 s is due to a 
solvent associated refractive index change. 
The slow decay in RU from 900 s to about 
2600 s is attributed to dissociation of a 
portion of the bound ApoE (non-covalently 
attached A$ does not dissociate from the 
chip under these conditions). After 2600 s 
sssentia!ly no further dissociation takes place. 
immobilized fibrils: immediate injection of a second 
aliyuot of fresh ApoE gives essentially no additional 
binding (data not shown). Previous studies have demon- 
strated binding of ApoE to A@ immobilized on an SPR 
chip under native buffer conditions [29]. In these pre- 
vious experiments, however, neither the aggregation 
state of the immobilized AP, nor the percentage of 
immobilized A@ that is covalently attached to the chip, 
are well defined. 
To gain a better understanding of the interaction of 
ApoE and A& a sample of solution phase ApoE-A@ co- 
aggregate was prepared and characterized [Zl]. l’he 
amount of Al3 in this isolated complex was determined 
by dot blot [Zl] analysis against an AI3 standard curve. In 
the thioflavin T assay (Materials and methods), 10 yg of 
Al3 fibrils gave a relative fluorescence signal of 7.4, while 
10 ~g AISeyuivalents (dot blot estimate) of the isolated 
ApoE-A@ complex gives a signal of 8.0. As stated above, 
the equivalent sensitivity of Al3 fibrils and ApoE-AI3 
co-aggregate to thioflavin T supports our interpretation 
that no appreciable aggregate formation occurs in the 
lag phase of the ApoE-containing reaction shown in 
Figure 1. 
Despite the structural similarity between A@ fibrils and 
ApoE-AP co-aggregates suggested by the thioflavin T 
data, there is a significant functional difference between 
the two aggregates. To examine the ability of ApoE-Al3 
complex to seed Al3 fibril formation, a fresh preparation 
was isolated and yuancified. In this experiment, the time 
lag co onset of aggregation for an unseeded Al3 mixture is 
four days (Fig. lb). Consistent with our previous report 
[ZZ], this time lag is cut to one day (i.e. fibrils form more 
rapidly) when seeded by the addition of 0.02 % by 
weight of aggregated monocomponent Al3 fibrils, and is 
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entirely eliminated when the reaction is seeded with 
10 % by weight of aggregated A@. 
In contrast, when parallel fibril formation reactions are 
treated with isolated ApoE-AB complex, instead of AB 
fibrils, quite different results are obtained (Fig. lb). When 
ApoE-AB complex is added to a level of 0.02 % by weight 
of A@, the time lag to onset of fibril formation is increased 
to two days, compared to the one day lag seen for mono- 
component AP fibrils. This is a significant effect; Figure 
la shows that it is necessary to increase the amount of 
inhibitory ApoE by loo-fold in order to obtain the same 
increase in time-lag from one day to two days. When the 
amount of ApoE-A@ complex is increased to IO % by 
weight of AB, the time lag to onset of fibril formation is 
four days, the same as for an unseeded reaction. Thus, in 
the experiment with 0.02 % by weight aggregated AB, 
added co-aggregate stimulates fibril formation compared 
to an unseeded control, but does so significantly less well 
than an equivalent amount of mono-component AB fibrils. 
In the experiment with 10 % by weight aggregated A@, 
added mono-component AB fibrils produce strong seeding 
of fibril formation, while added ApoE-AB coaggregate is 
entirely inert, exhibiting neither seeding {shorter Iag time) 
nor inhibition of nucleation (longer lag time). 
Complex formation appears to be relatively slow compared 
CO the fibril extension reaction, but the ApoE-AB complex, 
once formed, seems to be quite stable. When aggregated 
AB (10 % by weight) and free ApoE (23 nM tetramer, 
equivalent to the amount found in the control co- 
aggregate) are added to an AB incubation without prior co- 
incubation, fibril formation begins essentially immediately, 
giving the same kinetics as the reaction with a comparable 
amount of aggregated AB seed alone (Fig. lb). This indi- 
cates chat, under these conditions, formation of ApoE-Aj3 
inhibition complex in situ is relatively slow and cannot 
compete kinetically with A@ fibril extensions. In contrast, 
when isolated ApoE-AB complex is incubated in PBS at 
37” C for 24 h, and then added to a fresh fibril formation 
reaction, it produces the same time lag to onset of fibril 
formation as does a comparable amount of freshly isolated 
complex (data not shown). This indicates that the ApoE- 
AB complex, once formed, is quite stable. 
Although protein aggregation reactions generally exhibit, 
significant variability, the experiments described here 
are highly reproducible, perhaps because of our ability 
to rigorously eliminate pre-existing aggregates from com- 
mercial lots of AB 1261, and because of the presumed 
high degree of regular structure in amyloid fibrils [23,30]. 
The excellent reproducibility of the fundamental seed- 
ing phenomenon and its inhibition by ApoE has been 
demonstrated previously 1221. Fibril seeds stored for 
over six months produce the same aggregation kinetics 
as freshly generated fibril seeds (see Materials and 
methods). Three independently isolated samples of 
ApoE-AB complex produce identically diminished abil- 
ities to seed fibril formation reactions (data not shown). 
The SPR experiments were also repeated at least three 
times with identical results and ApoE isotypes gave 
similar binding to aggregates of AB(1-42) bound to sensor 
chips (data not shown). 
Discussion 
As outlined in the introduction, some previous results 
from this and other laboratories suggest that ApoE is an 
inhibitor of AB fibril formation, while other reports suggest 
that’it is either a stimulant of AB fibril formation, or at least 
can be incorporated into an ApoE-AP co-aggregate. It is 
important to know whether any of the reported properties 
of ApoE are responsible for the role of the ApoE gene as a 
risk factor in AD. It is also important to know whether 
ApoE Ts intrinsically helpful or hurtful in the development 
of AB aggregates and AD, since therapeutic application of 
ApoE, or of an ApoE mimic, is either indicated or concra- 
indicated depending on the fundamental role of the 
protein in the AD brain. 
The results described here, in addition to previous reports 
from this laboratory [21,22], can be interpreted according to 
the model shown in Figure 5. Lansbury and coworkers 
[31,323 have shown that fibril formation in simple pep- 
tide systems displays attributes of a nucleated growth 
mechanism, in which reaction mixtures display variable, 
concentration-dependent lag times to the onset of an 
aggregation reaction which, once engaged, proceeds 
rapidly. A diagram of how nucleation is presumed to 
proceed is shown at the top of Figure 5. Each step in the 
assembly of B from units of A (Fig. 5) is thermodynamically 
unfavorable, until the final step where sufficient internal 
contacts exist to provide a degree of stability to B. At this 
point, B has an extended lifetime in solution and sub- 
sequent additions of A are rapid, ending the observed lag 
phase in the, kinetics and generating the growing fibril D. 
Evans eta/. [IS] reported that, in such an AB fibril for- 
mation reaction, added ApoE (C in Fig. 5) can delay the 
onset of aggregation, presumably by binding to fihril- 
lization nuclei as they develop. This result, which we have 
confirmed ([ZZ] and results described here), is portrayed 
in the path from B co E to D in Figure 5. The simplest 
model for this inhibition is direct binding of ApoE to the 
growth face(s) of the nascent nucleus to form E. 
In agreement with the nucleated growth mechanism, it is 
possible to reduce or eliminate the lag time before onset 
of fibril formation by the addition of Al3 fibrils (‘seeding’; 
the F CO D path Fig. 5). We have shown that ApoE can 
also inhibit this seeding reaction by associating with the 
growing fibri1 to form a complex and prevent its extension 
into fibrils (F to G to D in Fig. 5) [2&Z]. 
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Figure 5 
A model for the observed effects of ApoE on 
co-aggregate formation with A/3 and on 
inhibiting fibril formation by AP. A!3 
components (A) self-associate weakly and 
reversibly until a critical size is reached which 
possesses some stability. This is the nucfeus 
for fibril formation (31, which at this point can 
add further AP components in a rapid growth 
phase to form fibrils (D). Association of ApoE 
(C) with B to form complex E blocks the 
growth termini of the nucleus, thus preventing 
its extension into fibrils. Fibril formation (D) can 
also be seeded by the addition of pre-formed 
fibrils (F) to a solution of AP. The model shows 
that ApoE can also associate with the growth 
surfaces of the added seed to form a complex 
(G), thus preventing its extension into fibrils. 
Finally, the modef shows that under 
appropriate conditions super-co-aggregates 
(H) of ApoE and AP can assemble from E or 
G. Thus, as indicated in Figure 1 b, newly 
generated nuclei l3, even in the absence of 
additional ApoE, can add to co-aggregates E 
to produce larger aggregates (H) with 
concommitant suppression of fibril nucleation. 
This schematic model is not meant to suggest 
any particular degree of linearity, regularity, or 
stoichiometry in the structures of ApoE-AP 
co-aggregates. For example, the tetrameric 
structure of the native ApoE molecule may 
introduce branch points in an ApoE-AP 
complex for recruitment and binding of 
additional AP complexes or other molecules. 
Here we report that the gel-filtration-isolated co-aggregate 
of A/3 and ApoE is itself a poor seed for fibril formation. 
This result is consistent with the model in Figure 5, 
suggesting that the isolated co-aggregate may resemble the 
presumptive inhibition complexes E and G. These ApoE- 
A@ complexes might be able to recruit additional ApoE 
from the reaction mixture, as well as additional emerging 
AP nuclei, thus supporting conversion of almost all free Ap 
into large co-aggregates H, as we have observed [Zl]. 
The picture that emerges from our in ~/ftro studies can 
be summarized as follows: ApoE is an effective inhibitor 
of fibril formation, acting via formation of co-aggregates 
of ApoE and AP that are seeding- and nucleation-inert, 
and hence represent inhibition complexes of fibril 
extension. As inhibition proceeds, given sufficient 
ApoE, levels of ApoE-AD inhibition complex can accu- 
mulate as the sole reaction product. This co-aggregate 
displays some of the dye-binding attributes of AP fibrils 
(see above), but it is distinctly different from mono- 
component AP fibrils in our only available measure of 
fibril function - the ability to seed further.fibril for- 
mation. Therefore, at high, non-physiological concen- 
trations of ApoE and A@, it might be possible to detect 
aggregation by thioflavin T binding - but it would be 
the. formation of seeding-incompetent ApoE- AP co- 
aggregates, and not mono-component AP fibrils, that are 
actually being measured. 
The studies discussed here show that the observation 
of aggregate formation with mixtures of ApoE and AP 
depends on the concentrations of AC3 and ApoE used and 
the means by which the aggregate is detected. We have 
not observed an acceleration of aggregate growth by 
added ApoE under any conditions. Nonetheless, it 
remains possible that even higher AP concentrations than 
those used here might produce such an acceleration. 
Alternatively, reports of stimulation of AP aggregation by 
ApoE may be based on other critical differences in the 
aggregation or detection protocols. As discussed here, 
some methods of detection of A@ amyloid fibrils can be 
misleading and might be misinterpreted. 
Our results argue that the aggregates formed in mixtures 
of ApoE and Ap are not fibrils of A@ alone, but are 
intimate co-aggregates of A@ and ApoE, and that these co- 
aggregates are functionally different from monocompo- 
nenc Aj3 fibrils. Since the ApoE-A/3 co-aggregates display 
some of the dye-binding properties of A@ fibrils (see 
above), our results are not incompatible with the observed 
fibrillar structure of ApoE-containing amyloid plaque 
isolated from brain tissue [4]. The basic fibrillar structure 
of the ApoE-AP co-aggregates makes their poor seeding 
ability all the more interesting, 
Significance 
The cytotoxicity in cell culture that has been demon- 
strated for both aggregated [331 and disaggregated 1341 
A@ has been cited as evidence for the importance of AP 
in disease processes. It may also be relevant, however, 
to examine the cellular effects of co-aggregates such as 
the ApoE-AP complex. Not only are brain plaques 
probably co-aggregates of AP and ApoE [4], but in 
addition the soluble ApoEAB co-aggregates that can be 
generated in V&-O 1211 may also exist in the brain, where 
their (probably transient) solubility might bestow on 
them unique cellular activities. 
Our observation that ApoE can bind to preformed 
fibrils and prevent their ability to be extended in a fib& 
forming growth phase suggests that it is not only an 
inhibitor of nucleation, but also of seeding (i.e. fibril 
extension). This has important implications for ther- 
apeutic strategies for control of amyloid plaque growth. 
Thus, ApoE, or another molecule with the same activity 
as ApoE, might be expected to effectively reduce the 
progress of plaque formation, even in brains already 
containing substantial quantities of amyloid. 
The ability of a growing fibril to incorporate other 
proteins into its structure may prove to be an important 
general mechanism not only of aggregate formatiov, 
but also of aggregate seeding, inhibition and toxicity. 
For example, we have suggested elsewhere [2’2] that 
other proteins that also inhibit fibril growth by binding 
to the growing fibril 122,353 may do so by becoming 
incorporated into the developing p-sheet network, 
providing an ‘end-cap’ that precludes extension. At the 
same time, fibrils derived from some other polypeptide 
sequences are apparently so structurally similar to AP 
that they are capable of ‘cross-seeding’ formation of Ap 
fibrils 1361. Finally, the ability of a growing protein 
aggregate to remove active protein molecules from 
solution may have a major role in the biologica 
consequences of prion formation [241. Thus, as we 
become increasingly aware of the high molecular selec- 
tivity of many forms of amyloid formation, it is impor- 
tant to recognize that the process may not be absolutely 
specific, and that: the potential misin-corporation of 
proteins into the growing fibril may have important bio- 
logical consequences. 
Materials and methods 
Materials 
The E3 variant of ApoE was produced in E. co/i /37] from cloned 
cDNA and purified under native conditions as described [21]. A@ was 
Research Paper ApoE-Ap inhibition complex Wetzel et al. 955 
purchased from Bachem. The experiments reported here were with the 
l-40 version of AP. 
Complex formation 
The general method for isolation of complexes under native conditions 
has been described [Zl]. To make the complex used in the 
experiments described here, AP(l-40) (45 PM) was incubated with 
5.3 PM (of tetramer) ApoE in PBS for 16 h at room temperature, 
centrifuged for 5 min at f5 000 tpm in an Eppendorf micrafuge, filtered 
through a 0.45 pm filter, and applied to a SMART (Pharmacia) 
microisolation system equipped with a Supetose 12 column 
equilibrated and run in phosphate-buffered saline, 1 mM EDTA, pH 7.4 
at 40 ~1 ml-’ at room temperature. Fractions containing the high- 
molecular weight co-aggregate peak were collected, their content of 
A@ quantified by dot blot analysis 1211, and their content of aggregated 
AP assessed by thioflavin T (thioflavin T assay) 1381 and Congo red 
binding [39]. These fractions were used to evaluate the seeding 
capability of the ApoE-Ap co-aggregate. 
Fibril formation 
To prepare AP depleted of aggregates for fibril formation reactions, 
peptide as obtained from the manufacturer tias dissolved at 5-l 5 mg 
ml-’ in HFIP (Sigma) and incubated at room temperature for 24 h then 
stored at -70” C in this solvent, as described previously i26]. A batch 
of fibril seeds [22] was prepared by incubating a 1 mg ml-1 PBS 
(Sigma) solution of Ap (prepared by dilution from an acetic acid stock 
solution of a non-HFtP-treated vial lot) at 37’ C for 3 days. Seed 
suspensions were aliquoted and stored at -70” C. To observe a 
nucleation dependent time-lag to the onset of fibril formation, it is 
important to remove the HFIP and resuspend the dry peptide rather 
than dilute into PBS from the HFtP stock [26]. Unless otherwise 
stated, fibril formation reactions were conducted unstirred and 
monitored by Congo red binding [26]. 
The Aj3 fibril seeds used in this experiment were stored for >6 months 
at -70” C. The functional stability of these seeds under these 
conditions is quite good, as indicated by the reproducible fibril 
formation progress curves conducted when the seeds were fresh [22] 
and after 6 months storage (Fig. 2). 
Fibril formation reactions under shaken conditions were conducted. as 
follows. A@ (400 kg) was treated with HFIP and the solvent was 
subsequently evaporated under vacuum. The peptide was suspended 
in 200 ~1 PBS to generate a 460 PM solution, which was filtered in a 
0.2 pm centrifugation filtration unit. The 180 ~1 of filtrate was split into 
two wells of a Ficrotitre plate. Into one well 20 &*I ApoE (0.8 mg ml-l 
in Pl3S) was added resulting in a final ApoE concentration of 1 PM 
(tetramer). Into the control well was added 20 p,l of PBS. The final 
concentration of AP was 380 PM in both wells. The plate was 
incubated, with shaking, at room temperature for 5 h. During this time, 
the microtitre plate absorbance at 405 nm was monitored. Aliquots 
(IO pg) were removed for Congo red binding analysis. 
Surface plasmon resonance 
AP, either with or without disaggregation by HFIP (see above), was 
covalently bound to the sensor chip via the peptide’s amino groups using 
the standard surface-activation chemistry (N-ethyl-w-/3-(dimathylamino)- 
propyllcarbodiimide hydrochloride plus N-hydroxysuccinimide) for 
modification of the carboxymethyidextran layer of the biosensor chip [40]. 
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